YD Bio (YDES) Common Equity (2024 - 2026)
YD Bio's (YDES) quarterly Common Equity came in at $4.5 million in Q2 2026, down 12.07% year-over-year from $5.1 million in Q2 2025, and up 256.67% quarter-over-quarter from -$2.9 million in Q4 2025.
Powered by 
Analysis
YD Bio (YDES) Common Equity (2024 - 2026) Analysis & Trends
YD Bio (YDES) has reported Common Equity for 3 consecutive years, with $4.5 million the latest figure, recorded in Q2 2026.
- On a quarterly basis, Common Equity fell 12.07% year-over-year to $4.5 million in Q2 2026; TTM through Jun 2026 was $4.5 million, a 12.07% decrease from a year earlier, with the FY2025 full-year figure at -$2.9 million, down 143.33% from the prior year.
- Common Equity was $4.5 million for Q2 2026 at YD Bio, up from -$2.9 million in the prior quarter.
- Over five years, Common Equity peaked at $6.6 million in Q4 2024 and troughed at -$2.9 million in Q4 2025.
- A 3-year average of $3.3 million and a median of $4.8 million in 2025 frame the typical range for Common Equity.
- Across the five-year window, Common Equity plunged 143.33% in 2025 and declined 12.07% in 2026, its largest moves.
- Over 3 years, Common Equity stood at $6.6 million in 2024, then sank by 143.33% to -$2.9 million in 2025, then jumped by 256.67% to $4.5 million in 2026.
- The last three Common Equity figures came in at $4.5 million (Q2 2026), -$2.9 million (Q4 2025), and $5.1 million (Q2 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 208.48 Bn | 194.49 Bn | 7.24 Bn | 11.69 Bn |
| 2 | Gilead Sciences | 186.29 Bn | 183.02 Bn | 6.22 Bn | 11.83 Bn |
| 3 | Vertex Pharmaceuticals | 128.79 Bn | 120.93 Bn | 2.84 Bn | 20.25 Bn |
| 4 | Regeneron Pharmaceuticals | 80.66 Bn | 72.67 Bn | 3.93 Bn | 31.71 Bn |
| 5 | Moderna | 61.46 Bn | 56.32 Bn | 52.00 Mn | 6.76 Bn |
| 6 | Argenx Se | 61.28 Bn | 56.10 Bn | 1.37 Bn | 8.42 Bn |
| 7 | Alnylam Pharmaceuticals | 32.04 Bn | 28.73 Bn | 992.69 Mn | 1.35 Bn |
| 8 | Biogen | 31.84 Bn | 30.56 Bn | 1.96 Bn | 18.85 Bn |
| 9 | Roivant Sciences | 28.74 Bn | 29.43 Bn | 1.16 Mn | 4.92 Bn |
| 10 | YD Bio | 225.82 Mn | 223.16 Mn | - | 4.47 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 4.47 Mn |
| Dec 31, 2025 | -2.86 Mn |
| Jun 30, 2025 | 5.09 Mn |
| Dec 31, 2024 | 6.59 Mn |
API Access
YD Bio Common Equity API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=common-equity&ticker=YDES&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "common-equity", "ticker": "YDES", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=common-equity&ticker=YDES&period=max&api_key=YOUR_API_KEY");
const data = await res.json();